Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis
MWN-AI** Summary
Orexo AB recently announced promising topline data from its clinical study OX640-002, which evaluated the efficacy of its innovative nasal rescue medication, OX640, in subjects with and without allergic rhinitis. OX640, a powder-based epinephrine formulation, aims to provide rapid treatment for allergic reactions, including anaphylaxis.
The trial explored both pharmacokinetic and pharmacodynamic profiles of OX640 in 30 participants, measuring epinephrine absorption and response to treatment. Key findings revealed that OX640 achieved clinically significant plasma epinephrine levels more quickly than a standard intramuscular injection. Notably, the absorption under conditions of allergic rhinitis was substantially accelerated, indicating that OX640 could be particularly effective for patients experiencing airway symptoms.
Results showed a dose-dependent increase in epinephrine levels, with OX640 generating pronounced increases in blood pressure and heart rate, important indicators of a successful anaphylaxis treatment. Additionally, the systemic safety profile aligned with established knowledge regarding epinephrine, and no severe adverse events were reported. This rigorous study confirms the potential of OX640 as a differentiated, needle-free alternative for anaphylaxis treatment.
Robert Rönn, Orexo's SVP and Head of R&D, expressed optimism about the findings, emphasizing that they will guide the final formulation and dosing of OX640, setting the stage for regulatory approval. The study not only reinforces the therapeutic promise of OX640 but also underscores Orexo's commitment to addressing substantial medical needs through innovative drug delivery technologies like its proprietary AmorphOX platform. As Orexo continues to advance its development, it positions itself at the forefront of solutions for urgent allergic responses, potentially transforming patient care in allergy management.
MWN-AI** Analysis
Orexo's recent announcement regarding the positive topline data from its clinical study of OX640, a nasal powder-based epinephrine treatment, signifies a potentially transformative development in emergency treatment for allergic reactions, including anaphylaxis. This study, conducted on subjects with and without allergic rhinitis, demonstrates that OX640 achieves clinically relevant plasma levels of epinephrine more rapidly than traditional intramuscular options, particularly in patients experiencing airway symptoms.
From an investment perspective, Orexo’s advancements in the OX640 program present a compelling opportunity. The data indicating faster absorption rates and enhanced efficacy in patients with allergic rhinitis highlight OX640’s potential competitive advantage over existing treatments. Moreover, the absence of serious adverse events during clinical trials further strengthens the product's marketability, indicating a favorable safety profile.
Market participants should consider Orexo’s strategic positioning within the lucrative epinephrine market. By addressing the critical need for an easy-to-use, needle-free alternative, OX640 can tap into a broad patient base, particularly as allergies are increasingly prevalent. Given these factors, investors might anticipate heightened market interest and increased stock liquidity leading up to and following any regulatory approvals.
It will be crucial for Orexo to leverage these positive study results for strategic partnerships and to solidify its market entry timeline. As such, monitoring regulatory updates and market feedback will be essential. The potential for OX640 to revolutionize anaphylaxis treatment—especially among those with additional airway complications—positions Orexo as a strong candidate for long-term investment, especially if commercial formulation decisions proceed swiftly.
In conclusion, optimism surrounding OX640's clinical efficacy could propel Orexo's stock performance, making it a stock worth watching in the biopharmaceutical sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
- OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of allergic reactions (incl. anaphylaxis) and is based on the proprietary AmorphOX® technology.
- The clinical study, OX640-002, evaluated both pharmacokinetic and pharmacodynamic effects of OX640 in subjects with and without allergic rhinitis.
- OX640 treatments achieved clinically relevant plasma levels of epinephrine more rapidly than the intramuscular reference product.
- Absorption from OX640 under allergic rhinitis conditions was significantly faster than under normal conditions, supporting rapid onset of effect also in patients with airway symptoms.
UPPSALA, Sweden , Jan. 10, 2025 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces positive topline results from the clinical study OX640-002. The study evaluated the performance in subjects with and without allergic rhinitis when treated with Orexo´s nasal rescue medication including powder-based epinephrine, OX640.
The study was a cross-over study in 30 subjects assessing absorption and pharmacodynamic effects of epinephrine from two doses of OX640, with one of the doses also administered during ongoing allergic rhinitis symptoms. Exposure was compared to a commercial intramuscular injection.
Topline data analysis demonstrates that OX640 treatments achieved mean epinephrine plasma levels associated with clinical efficacy more rapidly than the intramuscular injection, with dose-dependent exposure levels. Absorption under allergic rhinitis conditions was significantly faster than under normal conditions, supporting rapid onset of effect also in patients with significant airway symptoms. OX640 formulations typically produced more pronounced increases in blood pressure and heart rate than the intramuscular injection, which are key effects for treatment of anaphylaxis.
Systemic safety was in line with the known pharmacology of epinephrine and local effects were transient and tolerated. There were no severe or serious adverse events.
Robert Rönn, SVP and Head of R&D, said: "We are pleased with the outcome of the study which further support the utility of our OX640 epinephrine nasal powder for treatment of anaphylaxis, even in case of allergic rhinitis symptoms. Importantly, the study results allow us to decide on the final commercial formulation and dose, which is critical to advance the project towards regulatory approval. The data further reinforces our view that OX640 has the potential to be a unique and differentiated needle-free epinephrine product."
For further information please contact:
Nikolaj Sørensen, President and CEO
Lena Wange , IR & Communications Director
Robert Rönn, SVP and Head of R&D
Tel: +46 (0)18 780 88 00
E-mail: ir@orexo.com
About Orexo
Orexo is a Swedish pharmaceutical company with 30 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the U.S. market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2023 amounted to SEK 639 million , and the number of employees to 116. Orexo is listed on Nasdaq Stockholm's main list and is available as an ADR on OTCQX (ORXOY) in the U.S.
For more information on Orexo, visit www.orexo.com . Follow Orexo on X, LinkedIn, and YouTube.
About AmorphOX®
Orexo's proprietary drug delivery platform, AmorphOX, is a powder made up of particles which are built using a unique combination of a drug, carrier materials and, optionally, other ingredients. The particles are presented as an amorphous composite of the various ingredients providing for excellent chemical and physical stability, as well as rapid dissolution. The technology works for a broad scope of active ingredients and has been validated in several human clinical studies showing rapid and extensive drug exposure.
About study OX640-002
The study was a 4-period cross-over study in 30 otherwise healthy subjects with seasonal allergic rhinitis. The study was conducted off allergy season with no ongoing allergy symptoms in subjects. Epinephrine plasma levels, blood pressure and heart rate were collected after administration of two different doses of OX640 and 0.3 mg intramuscular epinephrine. In one treatment period, one of the OX640 doses was administered following nasal administration of allergens, producing acute allergic rhinitis symptoms in the subjects.
The information was submitted for publication at 2.00 pm CET on January 10 , 2025.
This information was brought to you by Cision http://news.cision.com .
The following files are available for download:
PR_Orexo announces positive topline data from clinical study of OX640_Jan 10 2025 |
SOURCE Orexo
FAQ**
How do the positive topline results from the clinical study of OX640 position Orexo AB ADR ORXOY in the competitive landscape of epinephrine delivery systems for allergic reactions and anaphylaxis?
What are the next steps for Orexo AB ADR ORXOY in advancing OX640 towards regulatory approval following the successful clinical results?
How might the faster absorption and onset of action under allergic rhinitis conditions enhance the market potential for OX640 and Orexo AB ADR ORXOY?
What implications do the study findings have for the final formulation and dosing of OX640, and how could this affect Orexo AB ADR ORXOY's commercialization strategy?
**MWN-AI FAQ is based on asking OpenAI questions about Orexo AB ADR (OTC: ORXOY).
NASDAQ: ORXOY
ORXOY Trading
237.22% G/L:
$2.60 Last:
100 Volume:
$2.60 Open:
